TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NORPRAMIN

DESIPRAMINE HYDROCHLORIDE
Neurology Approved 1964-11-20
2
Indications
--
Phase 3 Trials
61
Years on Market

Details

Status
Prescription
First Approved
1964-11-20
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: DESIPRAMINE HYDROCHLORIDE

NORPRAMIN Approval History

Loading approval history...

What NORPRAMIN Treats

1 indications

NORPRAMIN is approved for 1 conditions since its original approval in 1964. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Depression
Source: FDA Label

NORPRAMIN Boxed Warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studiesof major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality wit...

πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NORPRAMIN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

NORPRAMIN is indicated for the treatment of depression.

⚠️ BOXED WARNING

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studiesof major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use o...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.